We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics


  Gold Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Nov 2020 - 07 Nov 2020

Soluble Transferrin Receptor Investigated in Iron Deficiency Anemia

By LabMedica International staff writers
Posted on 25 May 2020
Print article
Image: The UniCel DxI 800 Access Immunoassay System (Photo courtesy of Beckman Coulter).
Image: The UniCel DxI 800 Access Immunoassay System (Photo courtesy of Beckman Coulter).
Anemia is a global public health problem and approximately 30% of the world's population suffered from anemia, with children and pregnant women being the most affected. Microcytic hypochromic anemia is a common type of anemia, and iron deficiency anemia (IDA) is the most common manifestation of this anemia.

The current gold standard for an IDA diagnosis is iron staining of a bone marrow smear. Transferrin receptor (TfR) is a transmembrane glycoprotein. Iron is transported by binding to specific TfR‐transferrin complex and thereby released into cells. Through proteolysis, TfR produces soluble transferrin receptor (sTfR) in the serum, whose concentration is proportional to the TfR concentration.

Laboratory medical scientists at the Peking Union Medical College Hospital (Beijing, China) enrolled 436 subjects from March 2014 to August 2015. Among these, 118 were patients with IDA, 161 were patients with anemia of chronic disease (ACD), 60 were patients with chronic diseases with iron deficiency anemia (CIDA), and 97 were apparently healthy subjects (HS).

The scientists used the DXI 800 automatic immunoassay analyzer (Beckman Coulter, Brea, CA, USA), the Cobas c702 automatic biochemistry analyzer (Roche Diagnostics, Risch-Rotkreuz, Switzerland), and the Siemens BNII special protein analyzer (Siemens Healthineers, Erlangen, Germany) with their corresponding sTfR reagents and calibrators. The sTfR concentrations in two groups of patient specimens with high‐level and low‐level sTfR concentrations and in quality control materials were measured four times a day for five consecutive days to evaluate the precision of the three methods.

The investigators reported that for the diagnosis of IDA, the cutoff points of sTfR measured by the chemiluminescent, immunoturbidimetric, and immunonephelometric assays were 2.91, 6.70, and 2.48 mg/L, respectively. The corresponding sensitivities were 85.59%, 85.59%, and 85.59%, the specificities were 91.47%, 90.31%, and 90.70%, and area under the curve was 0.943, 0.944, and 0.936, respectively. The sTfR concentrations measured by the different methods were significantly higher in the IDA and CIDA groups than in the other two groups.

The authors concluded that the different sTfR measurement methods showed similar diagnostic value in diagnosing iron deficiency and identifying whether ACD was combined with iron deficiency. However, there were large differences in the measurement results obtained with the different methods, and their cutoff points also varied. Therefore, when sTfR is used in the course of clinical diagnosis and treatment and to establish relevant diagnostic criteria and guidelines, clinicians should pay attention to the differences in the results between different measurement methods. The study was first published on April 22, 2020 in the Journal of Clinical Laboratory Analysis.

Print article
BIOHIT  Healthcare OY


Industry News

view channel
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)

Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership

The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.